The High Price of Hemophilia

An estimated 20,000 people in the U.S. are living with the inherited bleeding disorder hemophilia, and more than 60% of them have moderate or severe hemophilia requiring lifelong treatment with expensive drugs and clotting...

Online Exclusives

Merck to Shed Women’s Health Products, Shift Focus to Cancer Drugs

As part of an effort to focus on cancer drugs, vaccines, and animal health, drug manufacturer Merck plans to spin off $6.5 billion in...

Venture Capital Firm Directs $750 Million to Health and Biotech Start-Ups

Silicon Valley venture capital firm Andreessen Horowitz has launched Biofund III, a $750 million fund directed at health and biology start-ups like EQRx, which...

News

From the Blood Journals

WIB_icon

Can a CAR T-Cell “Cocktail” Overcome Antigen Escape?

A sequential infusion of 2 third-generation chimeric antigen receptor (CAR) T cells targeting CD19 and CD22, respectively, was associated with a high response rate...
WIB_icon

Novel JAK2 Insertion/Deletion Mutation Associated With Unique MPN Overlap Syndrome

In a small series of patients with myeloproliferative neoplasms (MPNs), a novel JAK2 insertion/deletion mutation, which the investigators termed JAK2ex13InDel, was found to drive...

Multimedia

Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL

Constantine S. Tam, MBBS, MD, discusses findings from the phase III SEQUOIA trial, in which 92% of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma...

Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline...

Nearly half of patients treated with acalabrutinib plus venetoclax and obinutuzumab achieved a complete response with undetectable minimal residual disease. Benjamin L. Lampson, MD,...

David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML

Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman,...

Jacqueline Garcia: Evaluating Navitoclax for Myelofibrosis

Jacqueline S. Garcia, MD, shares results from a phase II study of navitoclax, an investigational disease-modifying therapy for the treatment of myelofibrosis, which appears...

On Location

Can Biomarkers Predict Myeloma Patients’ Response to Venetoclax?

In an analysis of the phase III BELLINI trial, researchers identified 2 biomarkers that predict...

Acalabrutinib Treatment Superior to Obinutuzumab Plus Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia

Acalabrutinib, alone or combined with obinutuzumab, led to greater improvements in progression-free survival (PFS), compared...

ER-Based Protocol Improves the Accuracy of von Willebrand Disease Testing in Young Patients With Heavy Menstrual Bleeding

Watch our interview with Megan C. Brown, MD. Researchers at Children’s Healthcare of Atlanta (CHOA) have...

Decitabine Maintenance May Improve Survival in Older Patients With AML

One year of maintenance therapy with brief monthly courses of intravenous decitabine was associated with...

Perspectives on 2019’s New Hematology Drug Approvals

In 2019, the FDA approved several new therapies – or new indications for previously approved...

Updates on ASH Clinical Practice Guidelines in Development

In 2019, the American Society of Hematology (ASH) continued its efforts to develop and publish...

Latest Headlines

Advertisement

ASH Directions

ASH Directions

ASH Announces 2020 Scholar Awards and New ASH Clinical Practice Guidelines on ITP

Hats Off to the Recipients of the 2020 ASH Scholar Awards! The American Society of Hematology (ASH) has announced the 39 recipients of its 2020...
ASH Directions

Nancy Berliner Steps in as Editor-in-Chief of Blood, First Industry Datasets Submitted to ASH...

ASH Teams Up With Leukemia & Lymphoma Society to Connect Patients to Clinical Trials A collaboration between the American Society of Hematology (ASH) and The...

Sign up for our
eNewsletter!

The Society Pages

Moffitt Officials Resign, HHS Awards $319 Million to National Health Service Corps, and more

Edward P. Evans Foundation Awards $10 Million in Funding for MDS Research Washington University School of Medicine in St. Louis and Dana-Farber Cancer Institute in...
The Society Pages

Stephen Hahn Confirmed as FDA Commissioner, Beth Shaz Becomes AABB President, and more

Stephen Hahn Confirmed as FDA Commissioner The U.S. Senate voted 72−18 to confirm Stephen Hahn, MD, as the FDA’s new commissioner. President Donald Trump nominated...
The Society Pages

Remembering Esmail Zanjani, Augustine Perrotta, and more

Remembering Esmail D. Zanjani (1938 – 2019) Esmail D. Zanjani, PhD, passed away on October 5, 2019. A pioneer in fetal cell and gene therapy,...

The High Price of Hemophilia

An estimated 20,000 people in the U.S. are living with the inherited bleeding disorder hemophilia, and more than 60% of them have moderate or...

Does Value Mean Doing Less?

Over the past decade, the concept of improving value by avoiding excessive care has taken center stage in discussions about the U.S. health care...

Calculating the Costs of Clinical Trials

Patients eager to contribute to research may not be fully aware of the hidden costs of trial participation Of the three potential risks of participating...